Cocrystal Pharma, Inc. 10-K

Item 8. Financial Statements The consolidated financial statements of Cocrystal Pharma, Inc. required by this Item are described in Item 15 of this Annual Report on Form 10-K and are presented beginning on page F-1. 42 COCRYSTAL PHARMA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Certified Public Accounting Firm (PCAOB ID No. 572 ) F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations F-4 Consolidated Statements of Stockholders’ Equity F-5 Consolidated Statements of Cash Flows F-6 Notes to Consolidated Financial Statements F-7 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and Stockholders Cocrystal Pharma, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Cocrystal Pharma, Inc. (the “Company”) and subsidiaries as of December 31, 2025 and 2024, the related consolidated statements of operations, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company suffered a net loss from operations and used cash in operations, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters. We have served as the Company’s auditor since 2019. /s/ Weinberg & Company, P.A Los Angeles, California March 31, 2026 F- 2 COCRYSTAL PHARMA, INC. CONSOLIDATED BALANCE SHEETS (Dollars and shares in thousands, except per share data) December 31, 2025 December 31, 2024 Assets Current assets: Cash $ 7,025 $ 9,860 Restricted cash 75 75 Tax credit receivable 706 1,215 Prepaid expenses and other current assets 328 430 Total current assets 8,134 11,580 Property and equipment, net 93 153 Deposits 95 29 Operating lease right-of-use assets, net (including $ 152 and $ 42 to related party) 1,390 1,694 Total assets $ 9,712 $ 13,456 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $ 1,876 $ 2,127 Current maturities of operating lease liabilities (including $ 49 and $ 42 to related party) 334 301 Total current liabilities 2,210 2,428 Long-term liabilities: Operating lease liabilities (including $ 104 and $ 0 to related party) 1,171 1,505 Total long-term liabilities 1,171 1,505 Total liabilities 3,381 3,933 Commitments and contingencies - - Stockholders’ equity: Common stock $ 0.001 par value; 100,000 and 150,000 shares authorized as of December 31, 2025 and 2024, respectively; 13,784 and 10,174 shares issued and outstanding as of December 31, 2025 and 2024, respectively 13 10 Additional paid-in capital 348,567 342,931 Accumulated deficit ( 342,249 ) ( 333,418 ) Total stockholders’ equity 6,331 9,523 Total liabilities and stockholders’ equity $ 9,712 $ 13,456 See accompanying notes to consolidated financial statements. F- 3 COCRYSTAL PHARMA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars and shares in thousands, except per share data) 2025 2024 December 31, 2025 2024 Operating expenses: Research and development $ 5,055 $ 12,537 General and administrative 3,964 5,341 Total operating expenses 9,019 17,878 Loss from operations ( 9,019 ) ( 17,878 ) Other income (expense): Interest income, net 134 537 Foreign exchange gain (loss) 54 ( 163 ) Total other income, net 188 374 Net loss $ ( 8,831 ) $ ( 17,504 ) Net loss per common share, basic and diluted $ ( 0.78 ) $ ( 1.72 ) Weighted average number of common shares outstanding, basic and diluted 11,290 10,174 See accompanying notes to consolidated financial statements. F- 4 COCRYSTAL PHARMA, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (in thousands) Shares Amount Capital Deficit Equity Common Stock Additional Paid-in Accumulated Total Stockholders’ Shares Amount Capital Deficit Equity Balance as of December 31, 2023 10,174 $ 10 $ 342,288 $ ( 315,914 ) $ 26,384 Stock-based compensation - - 643 - 643 Net loss - - - ( 17,504 ) ( 17,504 ) Balance as of December 31, 2024 10,174 $ 10 $ 342,931 $ ( 333,418 ) $ 9,523 Sale of common stock in ATM, net of transaction costs 85 - 154 - 154 Stock-based compensation - - 270 - 270 Share issuance from RSU award 17 - - - - Sale of common stock and warrants, net of transaction costs 3,508 3 5,212 - 5,215 Net loss - - - ( 8,831 ) ( 8,831 ) Balance as of December 31, 2025 13,784 $ 13 $ 348,567 $ ( 342,249 ) $ 6,331 See accompanying notes to consolidated financial statements. F- 5 COCRYSTAL PHARMA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) 2025 2024 December 31, 2025 2024 Cash flows from operating activities: Net loss $ ( 8,831 ) $ ( 17,504 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense 72 126 Right of use assets 304 320 Stock-based compensation 270 643 Change in operating lease liabilities ( 301 ) ( 210 ) Changes in operating assets and liabilities: Tax credit receivable 509 ( 325 ) Prepaid expenses and other current assets 102 1,343 Deposits ( 66 ) 17 Accounts payable and accrued expenses ( 251 ) ( 895 ) Net cash used in operating activities ( 8,192 ) ( 16,485 ) Investing activities: Purchases of property and equipment ( 12 ) ( 8 ) Net cash used in investing activities ( 12 ) ( 8 ) Financing activities: Proceeds from the sale of common stock under ATM 154 - Proceeds from sale of common stock and warrants, net of transaction costs 5,215 - Net cash provided by financing activities 5,369 - Net decrease in cash and restricted cash ( 2,835 ) ( 16,493 ) Cash and restricted cash at beginning of period 9,935 26,428 Cash and restricted cash at end of period $ 7,100 $ 9,935 Supplemental disclosure: Non-cash investing and financing activities Initial recognition of right-of-use assets and lease liabilities $ - $ 163 See accompanying notes to consolidated financial statements. F- 6 COCRYSTAL PHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the years ended December 31, 2025 and 2024 1. Organization and Business . Cocrystal Pharma, Inc. (“we”, the “Company” or “Cocrystal”), a biopharmaceutical company, has been developing novel technologies and approaches with the goal of creating viable antiviral drug candidates since its initial funding in 2008. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prophylaxis of viral diseases in humans. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas. In September 2021, the Company opened a wholly owned foreign subsidiary in Australia named Cocrystal Pharma Australia, Ltd (“Cocrystal Australia”) with the objective of operating clinical trials in Australia. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying consolidated financial statements, for the year ended December 31, 2025, the Company recorded a net loss of approximately $ 8.8 million and used cash in operating activities of $ 8.2 million, and at December 31, 2025, the Company has an accumulated deficit of $ 342.2 million. As of December 31, 2025, the Company had an unrestricted cash balance of $ 7.0 million and working capital of approximately $ 5.9 million. We believe that our current resources will not be sufficient to fund our operations beyond the next 12 months. This estimate is based, in part, upon our currently projected expenditures. Due to ongoing research and development efforts, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these consolidated financial statements. The Company’s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances. Through December 31, 2025, the Company has primarily funded its operations through equity offerings. The Company will need to continue obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that the additional capital it is able to raise, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. Our future cash requirements, and the timing of those requirements, will depend on a number of factors, including economic conditions, the approval and success of our products in development, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and legal proceedings that may arise. We have historically not generated positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs. If the Company is unable to obtain adequate capital, it could be forced to substantially curtail its drug development activities or cease operations. The Company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases. F- 7 2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting of annual financial information. Principles of Consolidation The consolidated financial statements include the accounts of Cocrystal Pharma, Inc. and its wholly owned subsidiaries: Cocrystal Pharma Australia Pty, Ltd., Cocrystal Discovery, Inc., Cocrystal Merger Sub, Inc., Baker Cummins Corp. and Biozone Laboratories, Inc. Intercompany transactions and balances have been eliminated. Segments The Company’s Co-Chief Executive Officer and President (“CEO”) is our chief operating decision maker (“CODM”) and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single reportable segment composed of the consolidated financial results of Cocrystal Pharma, Inc. The measure of segment assets is reported on the consolidated balance sheets as total assets (see Note 12). Use of Estimates Preparation of the Company’s consolidated financial statements in conformance with U.S. GAAP requires the Company’s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to clinical trial costs and accruals and the fair value of stock-based compensation. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $ 250,000 for each institution accounts are held. At December 31, 2025 and 2024, our primary operating account held approximately $ 7,025,000 and $ 9,860,000 , respectively, and our collateral account balance of $ 75,000 as of December 31, 2025 and other cash accounts are maintained at different institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof. Risks and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, ability to obtain regulatory approvals, competition from currently available treatments and therapies, competition from larger companies, effective protection of proprietary technology, maintenance of strategic relationships, and dependence on key individuals. Products developed by the Company will require clearances from the U.S. Food and Drug Administration (the “FDA”) and other international regulatory agencies prior to commercial sales in their respective markets. The Company’s products may not receive the necessary clearances and if they are denied clearance, clearance is delayed, or the Company is unable to maintain clearance, the Company’s business could be materially, adversely impacted. F- 8 Cash and Restricted Cash The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents, and the Company held no cash equivalents as of December 31, 2025 and 2024. The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands): Schedule of Reconciliation of Cash and Restricted Cash December 31, 2025 December 31, 2024 Cash $ 7,025 $ 9,860 Restricted cash 75 75 Total cash and restricted cash shown in the statements of cash flows $ 7,100 $ 9,935 Restricted cash represents amounts pledged as collateral for financing arrangements that are currently limited to the issuance of business credit cards. The restriction will end upon the conclusion of these financing arrangements. Property and Equipment, net Property and equipment, which consists of lab equipment (including lab equipment under capital lease), computer equipment, and office equipment, is recorded at cost and depreciated over the estimated useful lives of the underlying assets (three to five years) using the straight-line method. Maintenance and repairs are charged directly to expense as incurred. Leases The Company accounts for its leases in accordance with ASC 842, Leases . The Company determines whether a contract is, or contains, a lease at inception. Operating lease right-of-use (“ROU”) assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ROU assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its understanding of what its credit rating would be. Fair Value Measurements FASB Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: Level 1 — quoted prices in active markets for identical assets or liabilities. Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. F- 9 The Company categorizes its cash and restricted cash as Level 1 fair value measurements. The Company categorizes its warrants potentially settleable in cash as Level 3 fair value measurements. The warrants potentially settleable in cash are measured at fair value on a recurring basis and are being marked to fair value at each reporting date until they are completely settled or meet the requirements to be accounted for as component of stockholders’ equity. The warrants are valued using the Black-Scholes option pricing model as discussed in Note 6 – Warrants. At December 31, 2025 the Company had 7,222,821 warrants outstanding and no warrants outstanding at December 31, 2024. At December 31, 2025 and 2024, the carrying amounts of financial assets and liabilities, such as cash, other assets, and accounts payable and accrued expenses approximate their fair values due to their short-term nature. Long-Lived Assets The Company regularly reviews the carrying value and estimated lives of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the asset’s fair value. Patent and Licensing Related Legal and Filing Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and related patent applications, all patent-related legal and filing fees and licensing-related legal fees are charged to operations as incurred. Patent and licensing-related legal and filing costs were $ 380,000 and $ 497,000 for the years ended December 31, 2025 and 2024, respectively. Patent and licensing related legal and filing costs are included in general and administrative costs in the Company’s consolidated statements of operations. Research and Development Expenses Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s clinical products. All research and development costs are expensed as incurred. Research and development costs are presented net of tax credits. The Company’s Australian subsidiary is entitled to receive government assistance in the form of refundable and non-refundable research and development tax credits from the federal and provincial taxation authorities, based on qualifying expenditures incurred during the fiscal year. The refundable credits are from the provincial taxation authorities and are not dependent on its ongoing tax status or tax position and accordingly are not considered part of income taxes. The Company records refundable tax credits as a reduction of research and development expenses when the Company can reasonably estimate the amounts and it is more likely than not; they will be received. During the year ended December 31, 2025, the Company recorded tax credits receivable of $ 661,910 . The amount remained outstanding at year end and was recorded as a reduction of research and development expense. Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense. F- 10 Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to employees, directors, and for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock option grants to employees, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Common Stock Purchase Warrants and Other Derivative Financial Instruments We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40, Contracts in Entity’s Own Equity . We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess the classification of our common stock purchase warrants and other freestanding derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. Net Income (Loss) per Share The Company accounts for and discloses net income (loss) per common share in accordance with FASB ASC Topic 260, Earnings Per Share . Basic income (loss) per common share is computed by dividing income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common stock for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands): Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share 2025 2024 December 31, 2025 2024 Outstanding options to purchase common stock 537 550 Warrants to purchase common stock 7,223 - Unvested restricted stock units 97 164 Total 7,857 714 F- 11 Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). ASU 2024-03 amends the FASB Accounting Standards Codification to require specified information about certain costs and expenses in the notes to the financial statements at each interim and annual reporting period, including disclosure of the amounts of purchases of inventory; employee compensation; depreciation; intangible asset amortization; and depreciation, depletion, and amortization included in each relevant expense caption on the face of the income statement within continuing operations that contains any of the expense categories previously listed. Disclosure will also be required of the total amount of selling expenses and an entity’s definition of selling expenses in annual reporting periods. ASU 2024-03 does not change or remove current expense disclosure requirements, but does affect where and how this information is presented in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027, and interim periods within annual reporting periods beginning January 1, 2028. Early adoption is permitted. The Company is in the process of evaluating ASU 2024-03 to determine its impact on the Company’s consolidated financial statement presentation and related disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statements, including their presentation and related disclosures. 3. Foreign Currency Remeasurement The U.S. dollar has been determined to be the functional currency for the net assets of Cocrystal Australia operations. The transactions are recorded in the local currencies and are remeasured at each reporting date using the historical rates for nonmonetary assets and liabilities and current exchange rates for monetary assets and liabilities at the balance sheet date. Exchange gains and losses from the remeasurement of monetary assets and liabilities are recognized in other income (loss). The Company recognized a gain of approximately $ 54,000 and a loss of approximately $ 163,000 for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025 and 2024, the Company’s cash and restricted cash balances consisted of the following (in thousands): Schedule of Cash Balance 2025 2024 U.S. Dollars $ 6,195 $ 9,554 Australian Dollars – in US $ 905 381 Cash Balance $ 7,100 $ 9,935 4. Property and Equipment Property and equipment as of December 31, consists of the following (table in thousands): Schedule of Property and Equipment 2025 2024 Lab equipment (excluding equipment under finance leases) $ 1,777 $ 1,765 Finance lease right-of-use lab equipment obtained in exchange for finance lease liabilities, net 162 162 Computer and office equipment 155 155 Total property and equipment 2,094 2,082 Less accumulated depreciation ( 2,001 ) ( 1,929 ) Property and equipment, net $ 93 $ 153 Depreciation expense was $ 72,000 and $ 126,000 for the years ended December 31, 2025 and 2024, respectively. F- 12 5. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following as of December 31, (table in thousands): Schedule of Accounts Payable and Accrued Expenses 2025 2024 Accounts payable $ 890 $ 1,542 Accrued compensation 85 117 Accrued other expenses 901 468 Total accounts payable and accrued expenses $ 1,876 $ 2,127 Accounts payable and accrued other expenses contain unpaid general and administrative expenses and costs related to research and development that have been billed and estimated unbilled, respectively, as of year-end. 6. Common Stock On June 27, 2024, the Company, following approval of the Company’s stockholders at the 2024 Annual Meeting of Stockholders filed an amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Amendment”) to decrease the number of shares of authorized capital stock of the Company from 155,000,000 shares of capital stock, consisting of 150,000,000 shares of common stock and 5,000,000 shares of preferred stock, to 101,000,000 shares of capital stock consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock. The Amendment became effective on June 27, 2024. As of December 31, 2025, the Company has authorized 100,000,000 shares of common stock, $ 0.001 par value per share. The Company had approximately 13,784,000 and 10,174,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively. The holders of common stock are entitled to one vote for each share of common stock held. At-The-Market Offering The Company is party to the At-The-Market Offering Agreement, dated July 1, 2020 (“ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may issue and sell over time and from time to time, to or through Wainwright, up to $ 10,000,000 of shares of the Company’s common stock. The Company sold 85,076 shares of its common stock at an average price of $ 1.88 under the ATM agreement during the three and nine months ended September 30, 2025. Prior to the termination of the ATM on September 12, 2025, the Company had sold a total 1,200,152 shares of its common stock for total net proceeds of approximately $ 2,380,000 pursuant to the ATM Agreement. On September 12, 2025, the Company and Wainwright agreed to terminate the sales of shares under the ATM Agreement and filed a prospectus supplement with the SEC to that effect. As a result of this, the at-the-market offering under the ATM Agreement is no longer ongoing as of September 12, 2025, and the Company will not make any sales of common stock pursuant to the ATM Agreement unless and until a new prospectus supplement is filed with the SEC; however, the ATM Agreement remains in full force and effect. Sale of common stock and warrants On October 28, 2025, we entered into a securities purchase agreement with four accredited investors under which the investors purchased a total of 743,024 units of the Company’s securities. The units were priced at-the-market under the rules of The Nasdaq Stock Market at a purchase price of $ 1.39 per unit. Each unit consisted of one share of common stock and one warrant to purchase two shares of common stock at an exercise price of $ 1.24 per share over a 27 -month period. The investors did not receive registration rights. The gross proceeds were $ 1,032,000 . The investors were four insiders of the Company. F- 13 On September 12, 2025, the Company, entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company sold to the investors (i) in a registered direct offering, an aggregate of 2,764,710 shares of the Company’s common stock, at a price of $ 1.70 per share and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of common stock (“the Investor Warrants”), at an initial exercise price of $ 1.50 per share. The Investor Warrants are exercisable upon issuance and will expire on September 27, 2027. Wainwright acted as the Company’s placement agent in connection with this offering. The Company paid Wainwright consideration consisting of (i) a cash fee equal to 7.0% of the aggregate gross proceeds in the offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds in the offering, (iii) reimbursement of certain expenses and (iv) warrants to acquire up to an aggregate of 207,353 shares of common stock (the “Placement Agent Warrants”) . The Placement Agent Warrants are similar to the Investor Warrants, except that the initial exercise price of the Placement Agent Warrants is $ 2.125 per share. The Company received net proceeds of $ 4,183,000 from the sale of its common shares and warrants in the direct offering. Warrants The following is a summary of activity in the number of warrants outstanding to purchase the Company’s common stock for the years ended December 31, 2025 and 2024 (table in thousands): Schedule of Activity of Warrants Outstanding Shares underlying warrants Weighted average Exercise price Aggregate Intrinsic Value Outstanding, December 31, 2024 - $ - - Exercised - - - Granted 7,222,821 1.46 - Expired - - - Outstanding, December 31, 2025 7,222,821 $ 1.46 - The Company had approximately 7,222,821 warrants outstanding as of December 31, 2025 and no warrants outstanding as of December 31, 2024. 7. Stock Based Awards Equity Incentive Plans The Company adopted an equity incentive plan in 2015 (the “2015 Plan”) under which 833,333 shares of common stock have been reserved for issuance to employees, and non-employee directors and consultants of the Company. Recipients of incentive stock options granted under the 2015 Plan shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2015 Plan is ten years . On June 16, 2021, the Company’s stockholders voted to approve an amendment to the 2015 Plan to increase the number of shares of common stock authorized for issuance under the 2015 Plan from 416,667 to 833,333 shares. The 2015 Plan expired on June 29, 2025 and no further equity awards will be issued under the 2015 Plan. On June 25, 2025, our stockholders approved and ratified an Equity Incentive Plan (the “2025 Plan”). The 2025 Plan provides for the grant of incentive stock options, qualified stock options, restricted stock awards, restricted stock units, stock appreciation rights, and performance shares or units and cash awards. Awards may be granted under the 2025 Plan to our employees, directors and independent contractors. the aggregate number of shares of Common Stock which shall be available for grants or payments of Awards under the 2025 Plan during its term shall initially be 1,500,000 (the “Total Plan Shares”). The Total Plan Shares will automatically increase on January 1st of each year, for a period of nine years commencing on January 1, 2026, in an amount equal to 5 % of the total number of shares of Common Stock outstanding as of December 31 of the preceding calendar year on a fully diluted basis. The 2025 Plan also provides that, notwithstanding the annual increase provision, in no event will the increase in Total Plan Shares available under the 2025 Plan pursuant to the increase provision exceed 2,500,000 additional shares (or a total of up to 4,000,000 Total Plan Shares), subject to adjustment as provided under the 2025 Plan. On April 2, 2025, the Board of Directors of the Company approved and adopted the 2025 Plan, which has an effective date of March 31, 2025. On June 25, 2025, the 2025 Plan was approved by our stockholders at our annual meeting of stockholders. As of December 31, 2025 there have been no equity awards issued under the 2025 Plan. Common Stock Reserved for Future Issuance The following table presents information concerning common stock available for future issuance (in thousands) as of December 31, 2025: Schedule of Roll-forward of Common Stock Available for Future Issuance Shares Available for Grant Balance at December 31, 2024 27 2015 Plan expiration ( 27 ) 2025 Plan approval 1,500 Balance at December 31, 2025 1,500 F- 14 Common Stock Reserved for Future Issuance The following table presents information concerning common stock available for future issuance as of December 31, (in thousands): Schedule of Common Stock Available for Future Issuance 2025 2024 Stock options issued and outstanding 537 550 Restricted stock units issued and outstanding 230 256 Shares authorized for future option grants 1,500 27 Warrants outstanding 7,223 - Total 9,490 833 Stock Options The following table summarizes stock option transactions for the 2015 and 2025 Plan, collectively, for year ended December 31, 2025 (in thousands, except per share amounts): Schedule of Stock Option Transactions Total Options Outstanding Weighted Average Exercise Price Aggregate Intrinsic Value Balance at December 31, 2023 558 $ 10.37 $ - - - Granted - - - Cancelled ( 8 ) - - Balance at December 31, 2024 550 $ 10.37 $ - Exercised - - - Granted - - - Cancelled ( 13 ) - - Balance at December 31, 2025 537 $ 8.91 $ - No options were granted during the years ended December 31, 2025 and 2024. For options granted and outstanding, there were 537,000 options outstanding which were fully vested or expected to vest, a weighted average exercise price of $ 8.91 and weighted average remaining contractual term of 6.25 years at December 31, 2025. For vested and exercisable options, outstanding shares totaled 512,000 . These options had a weighted average exercise price of $ 9.23 per share and a weighted-average remaining contractual term of 6.18 years at December 31, 2025. The aggregate intrinsic value of outstanding and exercisable options at December 31, 2025 was calculated based on the positive difference between the closing price of the Company’s common stock as reported on the Nasdaq Capital Market on December 31, 2025 of approximately $ 0.98 per share. As of December 31, 2025, total outstanding and exercisable options had no intrinsic value. Restricted Stock Units On August 12, 2024, the Company’s Compensation Committee approved the issuance of 256,000 restricted stock unit (“RSU”) awards to non-employee directors, officers, consultants and employees. The aggregate fair value of the restricted stock unit awards granted was estimated to be $ 451,000 using the market price of the stock on the date of the grant which is expensed using the straight-line method over the vesting period. Schedule of Restricted Stock Units Total Restricted Stock units Outstanding Weighted Average Fair Value Aggregate Intrinsic Value Unvested and expected to vest at December 31, 2024 164 $ 1.76 $ - Exercised - - - Forfeited ( 9 ) - - Vested ( 58 ) - - Unvested and expected to vest at December 31, 2025 97 $ 1.76 $ - The Company accounts for share-based awards to employees and nonemployee directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation. , and under the recently issued guidance following FASB’s pronouncement, ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting . Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. For the twelve months ended December 31, 2025 and 2024, equity-based compensation expense recorded on vested options and RSU was $ 270,000 and $ 643,000 , respectively. As of December 31, 2025, there was approximately $ 57,000 of total unrecognized compensation expense related to non-vested stock options that is expected to be recognized over a weighted average period of 0.371 years and as of December 31, 2025, there was approximately $ 165,000 of total unrecognized compensation expense related to non-vested RSU that is expected to be recognized over a weighted average period of 0.88 years. F- 15 8. Collaborations NIH/NIAID award On October 27, 2025, the Company issued a press release announcing it has received a $ 500,000 Small Business Innovation Research (“SBIR”) Phase I award from the National Institutes of Health (“NIH”) and the National Institute of Allergy and Infectious Diseases (NIAID). The NIH/NIAID Phase I award is designed to assess the scientific, technical and commercial potential of early-stage programs and will support the Company’s development of a novel, oral, broad-spectrum antiviral candidate for the treatment of influenza A and B infections. Phase 1b Clinical Trial On June 9, 2025 the Company engaged Emory University, a nonprofit research institution of higher education, to conduct a Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment. The cost of the agreement including protocol development, study performance and virology is budgeted at approximately $ 3 million. The Company has expensed $ 564,000 during the 2025 year, which includes $ 521,000 in accrued expense at December 31, 2025. Phase 2a Clinical Trial On August 3, 2022 the Company engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization (“CRO”), to conduct a Phase 2a clinical trial with the Company’s novel, broad-spectrum, orally administered antiviral influenza candidate. The Company prepaid a reservation fee of $ 1.7 million upon execution of the agreement and the reservation fee been fully expensed as of December 31, 2024, leaving no balance in prepaid and other expenses as of the prior year then ended. The total cost of the agreement (including the reservation fee) is approximately $ 6.9 million. Following an internal review and consultation, the Company is not in agreement with hVIVO Phase 2a clinical trial practices and is in discussions to resolve the matter. 9. Income Taxes The Company’s income (loss) before provision (benefit) for income taxes for years ended December 31, 2025 and 2024, respectively were generated in the following jurisdictions (in thousands): Schedule of Income (Loss) Before Provision (Benefit) for Income Taxes 2025 2024 Years Ended December 31, 2025 2024 Domestic ( 7,868 ) ( 15,898 ) Foreign ( 963 ) ( 2,729 ) Worldwide income ( 8,831 ) ( 18,627 ) In accordance with the authoritative guidance for income taxes under ASC 740, a deferred tax asset or liability is determined based on the difference between the financial statement and the tax basis of assets and liabilities as measured by the enacted tax rates, which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company recognizes the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. The Company’s practice is to recognize interest and/or penalties related to income tax matters as income tax expense. The Company is subject to taxation and files income tax returns in the United States, Australia and various state jurisdictions. All tax years from inception to date are subject to examination by the U.S. and state tax authorities due to the carry-forward of unutilized net operating losses and research and development credits. Currently, no years are under examination. As a result of operating loss and tax credit carryforward benefits being offset by valuation allowances, there is no current or deferred federal, state or foreign tax expense in 2025 or 2024. There were no federal, state or foreign tax payments in 2025. Significant components of the Company’s deferred income taxes at December 31, 2025 and 2024 are shown below (table in thousands): Schedule of Deferred Tax Assets and Liabilities 2025 2024 Deferred tax assets: Net operating loss carryforwards $ 26,325 $ 23,672 Compensation 550 666 Research and development tax credits 3,736 3,543 Capitalized and Research Expenditures 5,992 6,935 Other 674 789 Total deferred tax assets 37,277 35,605 Deferred tax liabilities: Property and equipment ( 10 ) ( 16 ) Other ( 303 ) ( 371 ) Total deferred tax liabilities ( 313 ) ( 387 ) Total deferred taxes, net 36,964 35,218 Valuation allowance ( 36,964 ) ( 35,218 ) Deferred tax liability, net $ - $ - F- 16 The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred tax assets will be realizable, the valuation allowance will be reduced. At December 31, 2025, the Company has federal and state net operating losses (“NOL”) carryforwards of approximately $ 122.5 million and $ 9.2 million, respectively. The federal and Florida NOL generated after 2017 of $ 60.9 million and $ 9.2 million, respectively, will carryforward indefinitely. The federal NOL carryforwards begin to expire in 2026 . At December 31, 2025, the Company had federal research credit carryforwards of approximately $ 3.7 million that expire in 2028. The above NOL carryforward and the research tax credit carryforward are subject to an annual limitation under the Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes, which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/382 analysis. If a change in ownership were to have occurred, NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, the reconciliation of taxes at the federal statutory rate to our provision for (benefit from) income taxes for the year ended December 31,2025 was as follows (in thousands, except for percentages): Schedule of Reconciliation of Federal Statutory Income Tax Rate Year Ended December 31, 2025 Tax Computed at federal statutory rate ( 1,855 ) 21.0 % State tax, net of federal income tax effect: 0.0 % Foreign tax effects: Australia: R&D Refund ( 204 ) 2.31 % Nondeductible research expenditures 439 ( 4.97 )% Other ( 33 ) ( 0.37 )% Effects of changes in tax laws or rates enacted in the current period: 0.00 % Effects of cross-border tax laws: 0.00 )% R&D Credits ( 193 ) 2.18 % Change in valuation allowance: 1,679 ( 19.01 )% Nontaxable or nondeductible items: Other 2 ( 0.02 )% Equity Compensation 165 ( 1.87 )% Other: Other 0.00 % Changes in Unrecognized Tax Benefits: 0.00 % The Company’s domestic operations are principally in the states of Washington and Florida. The reconciliation of taxes at the federal statutory rate to our provision for (benefit from) income taxes for the year December 31, 2024, in accordance with the guidance prior to the adoption of ASU 2023-09 was as follows: 2024 Statutory federal income tax rate 21.00 % Research credits 1.86 % Change in valuation allowance ( 20.14 )% Equity compensation ( 0.27 )% Foreign rate differential 1.32 % Other tax, credit and adjustments ( 3.78 )% Effective income tax rate 0.00 % On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to current deduction of domestic research expenses, increasing the limit of the deduction of interest expense deduction to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The impact of the tax law changes from the OBBBA is included in the Company’s financial statements. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 on a prospective basis effective January 1, 2025. 10. Lease Commitments Operating Leases The Company leases office space in Miami, Florida that expire on September 30, 2027 and two research and development laboratory spaces in Bothell, Washington under operating leases that expire on January 31, 2029 and January 31, 2031 , respectively. For operating leases, the weighted average discount rate is 6.4 % and the weighted average remaining lease term is 5.2 years. Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives. F- 17 The components of rent expense and supplemental cash flow information related to leases for the period are as follows (tables in thousands): Schedule of Components of Rent Expense and Supplemental Cash Flow Information Year Ended December 31, 2025 Year Ended December 31, 2024 Lease Cost Operating lease cost (included in operating expenses in the Company’s consolidated statements of operations) $ 410 $ 393 Other Information Cash paid for amounts included in the measurement of lease liabilities $ 400 $ 265 Weighted average remaining lease term – operating leases (in years) 4.3 5.2 Average discount rate – operating leases 6.4 % 6.4 % The supplemental balance sheet information related to leases for the period is as follows (tables in thousands): Schedule of Supplemental Balance Sheet Information At December 31, 2025 At December 31, 2024 Operating leases Long-term right-of-use assets of which $ 102 and $ 152 relates to related party, respectively, net of accumulated amortization of $ 570 and $ 266 , respectively $ 1,390 $ 1,694 Short-term operating lease liabilities, of which $ 56 and $ 49 relates to related party, respectively 334 301 Long-term operating lease liabilities, of which $ 47 and $ 104 relates to related party, respectively 1,171 1,505 Total operating lease liabilities $ 1,505 $ 1,806 Schedule of Maturities of Lease Liabilities Year ending December 31, (in thousands) 2026 419 2027 415 2028 376 2029 249 2030 and thereafter 264 Total minimum operating lease payments $ 1,723 Less: present value discount ( 218 ) Total operating lease liabilities $ 1,505 In April 2023, the Company renewed its lease for the unit 100 at the Bothel, Washington facility (“Bothel 100”) for an 84-month ( 7 years) term, starting February 1, 2024, and ending on January 31, 2031 . The Company classified the amended lease as an operating lease pursuant to the provisions of ASC 842 and calculated the discounted value of the total lease payments to be approximately $ 1,224,000 using a discount rate of 6 %. This amount was recognized as the lease liability and right-of use asset at the renewal date of the lease. As the renewal occurred in 2023, the Company deemed it appropriate to recognize both the right-of-use asset and lease liability for the extension term in 2023, with no amortization of the asset until the commencement of the extension term in February 2024. In September 2023, following the renewal of the Bothell 100 facility lease, the Company amended the agreement to expand the premises to include Suite 200 (“Bothell 200 facility”). The lease for the Bothell 200 facility has a 60-month ( 5 -year) term, running from February 1, 2024, through January 31, 2029 . The Company classified the lease as an operating lease and calculated the discounted value of the total lease payments to be approximately $ 571,000 , using a 6 % discount rate. This amount was recognized as the lease liability and right-of-use asset at the lease commencement date. As the lease for the Bothell 200 facility is tied to an existing lease and was executed in 2023, the Company deemed it appropriate to recognize both the right-of-use asset and lease liability in 2023, with no amortization of the asset until the lease term begins in February 2024. In August 2024, the Company renewed its lease for the Miami, Florida location for a 36 -month term, starting from October 1, 2024, and ending on September 30, 2027 , with an optional two-year extension. At the time of renewal, the Company classified the lease as an operating lease pursuant to the provisions of ASC 842 and calculated the discounted value of the total lease payments to be approximately $ 163,000 , using a discount rate of 10.75 %, and recognized this amount as the lease liability and right-of-use asset at renewal date. The lessor of the Miami, Florida lease is a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. See Note 11. The minimum lease payments above do not include common area maintenance (CAM) charges, which are contractual obligations under the Company’s Bothell, Washington lease, but are not fixed and can fluctuate from year to year. CAM charges for the Bothell, Washington facility is calculated and billed based on total common expenses for the building incurred by the lessor and apportioned to tenants based on square footage. In 2025 and 2024, approximately $ 169,000 and $ 174,000 of CAM charges for the Bothell, Washington lease was included in operating expenses in the consolidated statements of operations, respectively. F- 18 For the twelve months ended December 31, 2025 and 2024, operating lease expense, including short-term leases, finance leases and CAM charges, totaled approximately $ 578,000 and $ 568,000 , respectively, of which $ 63,000 and $ 62,000 , respectively was to a related party. 11. Transactions with Related Parties On August 14, 2024, the Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. On an annualized basis, straight-line rent expense is approximately $ 64,000 including fixed and estimable fees and taxes. Upon the extension of the lease, the Company recognized a right-of-use asset of approximately $ 163,000 . The discount rate used to measure the lease assets and liabilities for the extension was 10.75 %. The Company paid a lease deposit of $ 4,000 on the original agreement and total rent and other expenses paid in connection with this lease were $ 63,000 and $ 62,000 for the years ended December 31, 2025 and 2024 respectively. 12. Segment information The Company operates and manages its business as one reportable and operating segment dedicated to the research and development Company’s novel orally administered antiviral influenza candidate. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis. The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on net income (loss). Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM (table in thousands): Schedule of Segment Information 2025 2024 Year ended December 31, 2025 2024 Revenue $ - $ - Less: Research and development 4,081 10,785 Salaries and personnel costs 1,573 2,900 Insurance 241 286 Stock-based compensation 270 643 Other operating expenses 2,854 3,264 Other income ( 188 ) ( 374 ) Net loss $ ( 8,831 ) $ ( 17,504 ) F- 19 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures Not applicable.